Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Analysis & Investment Frameworks
Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock analysis on Invetso. Review Corbus Pharmaceuticals Holdings, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Corbus Pharmaceuticals Holdings, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Corbus Pharmaceuticals Holdings, Inc. Key Financial Metrics
- Market Cap: $58.77M
- Revenue: $N/A
- ROE: -87.05%
- ROIC: -100.35%
- Dividend Yield: N/A
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.